Free Trial
→ Your book attached (From Profits Run) (Ad)tc pixel Free RENX Stock Alerts

Renalytix (RENX) Competitors

Renalytix logo
GBX 1.98 +0.18 (+10.00%)
As of 06/5/2026 07:45 AM Eastern
Compare

RENX vs. COG, INHC, FDBK, IQAI, and DVRG

Should you buy Renalytix stock or one of its competitors? MarketBeat compares Renalytix with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Renalytix include Cambridge Cognition (COG), Induction Healthcare Group (INHC), Feedback (FDBK), IQ-AI (IQAI), and DeepVerge (DVRG). These companies are all part of the "health information services" industry.

How does Renalytix compare to Cambridge Cognition?

Renalytix (LON:RENX) and Cambridge Cognition (LON:COG) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, earnings, media sentiment, analyst recommendations, valuation, profitability, dividends and risk.

14.0% of Renalytix shares are held by institutional investors. Comparatively, 15.9% of Cambridge Cognition shares are held by institutional investors. 5.1% of Renalytix shares are held by company insiders. Comparatively, 3.3% of Cambridge Cognition shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Cambridge Cognition has a consensus target price of GBX 56, indicating a potential upside of 51.35%. Given Cambridge Cognition's stronger consensus rating and higher probable upside, analysts plainly believe Cambridge Cognition is more favorable than Renalytix.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Renalytix
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Cambridge Cognition
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00

Cambridge Cognition has higher revenue and earnings than Renalytix. Cambridge Cognition is trading at a lower price-to-earnings ratio than Renalytix, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Renalytix£3.30M2.62-£109.93M-£4.00N/A
Cambridge Cognition£9.40M1.83-£1.58M-£3.90N/A

Renalytix has a beta of 1.974, suggesting that its share price is 97% more volatile than the broader market. Comparatively, Cambridge Cognition has a beta of 0.73, suggesting that its share price is 27% less volatile than the broader market.

Cambridge Cognition has a net margin of -17.82% compared to Renalytix's net margin of -680.00%. Renalytix's return on equity of 274.67% beat Cambridge Cognition's return on equity.

Company Net Margins Return on Equity Return on Assets
Renalytix-680.00% 274.67% -93.54%
Cambridge Cognition -17.82%-62.89%-0.30%

In the previous week, Renalytix's average media sentiment score of 0.00 equaled Cambridge Cognition'saverage media sentiment score.

Company Overall Sentiment
Renalytix Neutral
Cambridge Cognition Neutral

Summary

Cambridge Cognition beats Renalytix on 9 of the 14 factors compared between the two stocks.

How does Renalytix compare to Induction Healthcare Group?

Renalytix (LON:RENX) and Induction Healthcare Group (LON:INHC) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, risk, profitability, dividends, analyst recommendations, earnings, institutional ownership and valuation.

Induction Healthcare Group has higher revenue and earnings than Renalytix. Induction Healthcare Group is trading at a lower price-to-earnings ratio than Renalytix, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Renalytix£3.30M2.62-£109.93M-£4.00N/A
Induction Healthcare Group£12.57M0.72-£5.12M-£5.54N/A

Induction Healthcare Group has a net margin of -23.86% compared to Renalytix's net margin of -680.00%. Renalytix's return on equity of 274.67% beat Induction Healthcare Group's return on equity.

Company Net Margins Return on Equity Return on Assets
Renalytix-680.00% 274.67% -93.54%
Induction Healthcare Group -23.86%-14.58%-7.32%

Renalytix has a beta of 1.974, indicating that its stock price is 97% more volatile than the broader market. Comparatively, Induction Healthcare Group has a beta of -0.41, indicating that its stock price is 141% less volatile than the broader market.

In the previous week, Renalytix's average media sentiment score of 0.00 equaled Induction Healthcare Group'saverage media sentiment score.

Company Overall Sentiment
Renalytix Neutral
Induction Healthcare Group Neutral

14.0% of Renalytix shares are held by institutional investors. Comparatively, 46.3% of Induction Healthcare Group shares are held by institutional investors. 5.1% of Renalytix shares are held by company insiders. Comparatively, 54.6% of Induction Healthcare Group shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

Induction Healthcare Group beats Renalytix on 6 of the 11 factors compared between the two stocks.

How does Renalytix compare to Feedback?

Feedback (LON:FDBK) and Renalytix (LON:RENX) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, media sentiment, valuation, institutional ownership, earnings, profitability, risk and analyst recommendations.

Renalytix has a net margin of -680.00% compared to Feedback's net margin of -845.25%. Renalytix's return on equity of 274.67% beat Feedback's return on equity.

Company Net Margins Return on Equity Return on Assets
Feedback-845.25% -135.17% -22.99%
Renalytix -680.00%274.67%-93.54%

In the previous week, Feedback's average media sentiment score of 0.00 equaled Renalytix'saverage media sentiment score.

Company Overall Sentiment
Feedback Neutral
Renalytix Neutral

Feedback has higher earnings, but lower revenue than Renalytix. Renalytix is trading at a lower price-to-earnings ratio than Feedback, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Feedback£849.62K3.76-£10.84M-£15.74N/A
Renalytix£3.30M2.62-£109.93M-£4.00N/A

34.7% of Feedback shares are held by institutional investors. Comparatively, 14.0% of Renalytix shares are held by institutional investors. 8.0% of Feedback shares are held by insiders. Comparatively, 5.1% of Renalytix shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Feedback has a beta of 0.77, suggesting that its share price is 23% less volatile than the broader market. Comparatively, Renalytix has a beta of 1.974, suggesting that its share price is 97% more volatile than the broader market.

Summary

Feedback beats Renalytix on 6 of the 11 factors compared between the two stocks.

How does Renalytix compare to IQ-AI?

Renalytix (LON:RENX) and IQ-AI (LON:IQAI) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, valuation, institutional ownership, risk, media sentiment, earnings, dividends and profitability.

IQ-AI has a net margin of -77.52% compared to Renalytix's net margin of -680.00%. Renalytix's return on equity of 274.67% beat IQ-AI's return on equity.

Company Net Margins Return on Equity Return on Assets
Renalytix-680.00% 274.67% -93.54%
IQ-AI -77.52%-140.75%-22.03%

In the previous week, Renalytix's average media sentiment score of 0.00 equaled IQ-AI'saverage media sentiment score.

Company Overall Sentiment
Renalytix Neutral
IQ-AI Neutral

IQ-AI has lower revenue, but higher earnings than Renalytix.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Renalytix£3.30M2.62-£109.93M-£4.00N/A
IQ-AI£538.19K3.30N/AN/AN/A

14.0% of Renalytix shares are held by institutional investors. 5.1% of Renalytix shares are held by company insiders. Comparatively, 66.0% of IQ-AI shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Renalytix has a beta of 1.974, indicating that its share price is 97% more volatile than the broader market. Comparatively, IQ-AI has a beta of 2.25, indicating that its share price is 125% more volatile than the broader market.

Summary

IQ-AI beats Renalytix on 5 of the 9 factors compared between the two stocks.

How does Renalytix compare to DeepVerge?

DeepVerge (LON:DVRG) and Renalytix (LON:RENX) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, earnings, risk, dividends, media sentiment, institutional ownership, analyst recommendations and profitability.

In the previous week, DeepVerge's average media sentiment score of 0.00 equaled Renalytix'saverage media sentiment score.

Company Overall Sentiment
DeepVerge Neutral
Renalytix Neutral

DeepVerge has a net margin of -19.81% compared to Renalytix's net margin of -680.00%. Renalytix's return on equity of 274.67% beat DeepVerge's return on equity.

Company Net Margins Return on Equity Return on Assets
DeepVerge-19.81% -10.27% -5.56%
Renalytix -680.00%274.67%-93.54%

DeepVerge has a beta of 1.07, meaning that its stock price is 7% more volatile than the broader market. Comparatively, Renalytix has a beta of 1.974, meaning that its stock price is 97% more volatile than the broader market.

4.2% of DeepVerge shares are owned by institutional investors. Comparatively, 14.0% of Renalytix shares are owned by institutional investors. 9.5% of DeepVerge shares are owned by insiders. Comparatively, 5.1% of Renalytix shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

DeepVerge has higher revenue and earnings than Renalytix. Renalytix is trading at a lower price-to-earnings ratio than DeepVerge, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
DeepVerge£12.41M0.00-£2.46M-£0.01N/A
Renalytix£3.30M2.62-£109.93M-£4.00N/A

Summary

DeepVerge beats Renalytix on 6 of the 10 factors compared between the two stocks.

Get Renalytix News Delivered to You Automatically

Sign up to receive the latest news and ratings for RENX and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

RENX vs. The Competition

Export
MetricRenalytixHealth Information Services IndustryMedical SectorLON Exchange
Market Cap£8.08M£316.69M£6.66B£2.75B
Dividend YieldN/A5.59%2.67%6.16%
P/E Ratio-0.50230.3620.31366.37
Price / Sales2.62132.25516.1887,126.19
Price / Cash1.8447.1426.9927.85
Price / Book-0.185.4610.247.68
Net Income-£109.93M-£22.78M£3.57B£5.89B
7 Day Performance23.75%-0.93%-1.28%-0.50%
1 Month Performance-1.00%0.62%1.38%1.84%
1 Year Performance-72.69%-10.76%23.93%72.87%

Renalytix Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
RENX
Renalytix
N/AGBX 1.98
+10.0%		N/A-72.7%£8.08M£3.30MN/A102
COG
Cambridge Cognition
1.3664 of 5 stars		GBX 37
flat		GBX 56
+51.4%		-5.1%£17.23M£9.40MN/A80
INHC
Induction Healthcare Group
N/AGBX 9.75
flat		N/A+4.2%£9.00M£12.57MN/A74
FDBK
Feedback
N/AGBX 8
-1.2%		N/A-50.2%£3.51M£849.62KN/A24
IQAI
IQ-AI
N/AGBX 0.80
flat		N/A+0.0%£1.77M£538.19KN/A6

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (LON:RENX) was last updated on 6/7/2026 by MarketBeat.com Staff.
From Our Partners
June 12: $100 Turns Into $100,000?
The SpaceX IPO is scheduled for June 12, and former tech executive Jeff Brown - who identified Bitcoin, Tesla,...
Brownstone Research | Sponsoredtc pixel
$30 stock to buy before Starlink goes public (WATCH NOW!)
In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...
Paradigm Press | Sponsoredtc pixel
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
Your book attached
Your Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...
Profits Run | Sponsoredtc pixel
SpaceX just filed. The clock is ticking.
Reuters reports Elon Musk filed secretly. Barron's says it's being finalized behind closed doors. CNBC just re...
The Oxford Club | Sponsoredtc pixel
My feud with Zohran Mamdani
Emmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...
Stansberry Research | Sponsoredtc pixel
SpaceX will mint billionaires. You won't be one of them.
By the time a company goes public, 95% of profits have already been made. Insiders bought SpaceX at $20 billio...
Behind the Markets | Sponsoredtc pixel